Literature DB >> 1544426

Reduced-bond tight-binding inhibitors of HIV-1 protease. Fine tuning of the enzyme subsite specificity.

J Urban1, J Konvalinka, J Stehlíková, E Gregorová, P Majer, M Soucek, M Andreánsky, M Fábry, P Strop.   

Abstract

Truncation of a peptide substrate in the N-terminus and replacement of its scissile amide bond with a non-cleavable reduced bond results in a potent inhibitor of HIV-1 protease. A series of such inhibitors has been synthesized, and S2-S3' subsites of the protease binding cleft mapped. The S2 pocket requires bulky Boc or PIV groups, large aromatic Phe residues are preferred in P1 and P1' and Glu in P2'. The S3' pocket prefers Phe over small Ala or Val. Introduction of a Glu residue into the P2' position yields a tight-binding inhibitor of HIV-1 protease, Boc-Phe-[CH2-NH]-Phe-Glu-Phe-OMe, with a subnanomolar inhibition constant. The relevant peptide derived from the same amino acid sequence binds to the protease with a Ki of 110 nM, thus still demonstrating a good fit of the amino acid residues into the protease binding pockets and also the importance of the flexibility of P1-P1' linkage for proper binding. A new type of peptide bond mimetic, N-hydroxylamine -CH2-N(OH)-, has been synthesized. Binding of hydroxylamino inhibitor of HIV-1 protease is further improved with respect to reduced-bond inhibitor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544426     DOI: 10.1016/0014-5793(92)80010-e

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

1.  Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody.

Authors:  J Lescar; J Brynda; P Rezacova; R Stouracova; M M Riottot; V Chitarra; M Fabry; M Horejsi; J Sedlacek; G A Bentley
Journal:  Protein Sci       Date:  1999-12       Impact factor: 6.725

2.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.

Authors:  E Alteri; G Bold; R Cozens; A Faessler; T Klimkait; M Lang; J Lazdins; B Poncioni; J L Roesel; P Schneider
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

4.  Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease.

Authors:  Ravikiran S Yedidi; Joseck M Muhuhi; Zhigang Liu; Krisztina Z Bencze; Kyriacos Koupparis; Carrie E O'Connor; Iulia A Kovari; Mark R Spaller; Ladislau C Kovari
Journal:  Biochem Biophys Res Commun       Date:  2013-08-03       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.